Immune Response News and Research

RSS

People may have a pre-existing immune response to COVID-19 thanks to common colds

Now, a new study shows that some people have immune responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, thanks to how the body reacted the last time it caught a cold. This means that even if a person has not been exposed to the novel coronavirus, the body has a memory of it and can trigger an immune response to fight the infection.

10 Aug 2020

Scientists identify new treatment targets for blinding retinal disease

When the eye isn't getting enough oxygen in the face of common conditions like premature birth or diabetes, it sets in motion a state of frenzied energy production that can ultimately result in blindness, and now scientists have identified new points where they may be able to calm the frenzy and instead enable recovery

10 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.

7 Aug 2020

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Galit Alter, PhD, Group Leader at the Ragon Institute of MGH, MIT and Harvard and Professor of Medicine at Harvard Medical School, and Helen Chu, MD, Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, and UW Medicine physician, have recently published a paper which identifies five immune response markers which, collectively, were able to correctly classify both convalescent COVID-19 patients and those who did not survive the disease.

7 Aug 2020

Advanced analysis offers new insights into immune system’s role in severe COVID-19

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease.

7 Aug 2020

Immune system derails during severe course of COVID-19

Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

6 Aug 2020

COVID-19: BCG vaccine is safe and possibly has a positive effect

The BCG vaccine, a vaccine originally made against tuberculosis, has a general stimulating effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.

6 Aug 2020

Nine teams awarded UTHSC/UofM CORNET grant for COVID-19 research

Nine research teams are awardees of the 2020 University of Tennessee Health Science Center/University of Memphis SARS-CoV-2/COVID-19 Research CORNET grants.

6 Aug 2020

America’s obesity epidemic threatens effectiveness of any COVID vaccine

For a world crippled by the coronavirus, salvation hinges on a vaccine.

6 Aug 2020

Carefully engineered spike protein can help develop COVID-19 vaccine

The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.

6 Aug 2020

Cats susceptible to and potential reservoirs for novel coronavirus

The study published on the preprint server bioRxiv in August 2020 shows that this is indeed taking place, with pet cats being infected and passing on the infection to contacts. It also offers the chance to see how the disease progresses in a susceptible host.

6 Aug 2020

Immune Response News and Research

People may have a pre-existing immune response to COVID-19 thanks to common colds

Scientists identify new treatment targets for blinding retinal disease

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

New platform shows potential to generate most effective vaccines with fewest side effects

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Advanced analysis offers new insights into immune system’s role in severe COVID-19

Immune system derails during severe course of COVID-19

COVID-19: BCG vaccine is safe and possibly has a positive effect

Nine teams awarded UTHSC/UofM CORNET grant for COVID-19 research

America’s obesity epidemic threatens effectiveness of any COVID vaccine

Carefully engineered spike protein can help develop COVID-19 vaccine

Cats susceptible to and potential reservoirs for novel coronavirus

COVID-19 should be treated as an acute inflammatory disease, Massey scientist says

NIH-Moderna investigational vaccine protects mice from infection with SARS-CoV-2

Evidence for antibody longevity in COVID-19 patients

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News